

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Thursday 6 September, from 10am to 2pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:		
1.	Dr Amanda Adler (Chair)	Present for all notes
2.	Dr Sanjeev Patel (Vice-Chair)	Present for all notes
3.	Professor John Cairns	Present for all notes
4.	Mr Mark Chapman	Present for all notes
5.	Mr Diar Fattah	Present for all notes
6.	Ms Susan Faulds	Present for all notes
7.	Dr Mark Glover	Present for all notes
8.	Mr Richard Hoddes	Present for all notes
9.	Dr Mona Johnson	Present for all notes
10.	Dr Nicholas Latimer	Present for all notes
11.	Mr Christopher O'Regan	Present for all notes
12.	Professor Stephen Palmer	Present for all notes
13.	Professor Allyson Pollock	Present for all notes
14.	Dr Stephen Smith	Present for all notes
15.	Professor Nicky Welton	Present for all notes
16.	Mr Nigel Westwood	Present for all notes
17.	Professor Sarah Wild	Present for all notes

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Sandra Aleknavice	Administrator, National Institute for Health and Care Excellence	Present for all notes
Adam Brooke	Technical Analyst, National Institute for	Present for all notes

Health and Care Excellence		
Ahmed Elsada	Technical Adviser, National Institute for Health and Care Excellence	Present for all notes
Dr Nasuh Büyükkaramikli	Health Economics Researcher Kleijnen Systematic Reviews	Present for notes 1 to 15
Dr Rob Riemsma	Reviews Manager Kleijnen Systematic Reviews	Present for notes 1 to 15
Professor David Linch	Consultant Haematologist, Head of Haematology Department, Director of BRS Cancer Programme, UCLH – clinical expert, nominated by Gilead	Present for notes 7 to 15
Professor Andrew Pettitt	Honorary Consultant Haematologist, University of Liverpool & Clatterbridge Cancer Centre NHS Foundation Trust – clinical expert, nominated by the NCRI-ACP-RCP-RCR	Present for notes 7 to 15

Non-public attendees:

Patience Kunonga	NIHR Innovation Observatory	Present for notes all notes
Michelle O'Rouke	NIHR Innovation Observatory	Present for notes all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of idelalisib for treating follicular lymphoma refractory to 2 treatments.
2. The Chair informed the Committee of the non-public observers at this meeting: Patience Kunonga and Michelle O'Rouke.
3. Apologies were received from Dr Carlo Berti, Dr Sanjay Kinra, Mr William Turner and Dr Stuart Williams.

Any other Business

4. The Committee were given an update on the progress and timelines for other appraisals they have considered at previous meetings.

Notes from the last meeting

- 5.
6. The committee approved the minutes of the committee meeting held on 2 August 2018 were approved.

Appraisal of idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379]

Part 1 – Open session

7. The Chair welcomed the invited experts: Dr Nasuh Büyükkaramikli, Dr Rob Riemsma, Professor David Linch and Professor Andrew Pettitt to the meeting and they introduced themselves to the Committee.
8. The Chair welcomed company representatives from Gilead to the meeting.
9. The Chair asked all Committee members to declare any relevant interests
 - 9.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Stephen Palmer, Professor Allyson Pollock, Dr Stephen Smith, Professor Nicky Welton, Mr Nigel Westwood and Professor Sarah Wild all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379].
10. The Chair asked all NICE Staff to declare any relevant interests.
 - 10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379].
11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 11.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379].

- 11.2. Professor David Linch declared a personal specific financial interest as he has given paid lectures for Gilead.
 - 11.2.1. It was agreed that this declaration would not prevent Professor Linch from participating in this section of the meeting.
- 11.3. Professor Andrew Pettitt declared a personal specific financial interest as he has received payment to cover the costs of attending scientific meetings and research funding from Gilead and from other companies including Celgene, Napp and Roche..
 - 11.3.1. It was agreed that this declaration would not prevent Professor Linch from participating in this section of the meeting.
12. The Chair introduced the lead team, Mr Diar Fattah, Professor Stephen Palmer and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379].
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
15. The Chair then thanked the experts, Evidence Review Group and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.
17. The Committee continued to discuss the clinical and cost effectiveness of idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379].
 - 17.1. The committee decision was based on consensus.
18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

19. Wednesday 3 October 2018 at 10 Spring Gardens, London SW1A 2BU.